Publications by authors named "R A DePinho"
Pancreatic ductal adenocarcinoma (PDAC) poses a grim prognosis for patients. Recent multidisciplinary research efforts have provided critical insights into its genetics and tumor biology, creating the foundation for rational development of targeted and immune therapies. Here, we review the PDAC genomic landscape and the role of specific oncogenic events in tumor initiation and progression, as well as their contributions to shaping its tumor biology.
View Article and Find Full Text PDFArticle Synopsis
- Advanced pancreatic ductal adenocarcinomas (PDACs) have a poor response to all existing therapies, making effective treatment a significant challenge for patients with late-stage disease.
- Researchers discovered a new chemo-induced signaling network that contributes to chemoresistance in PDAC, highlighting Yap1 in cancer cells and Cox2 in stromal fibroblasts as critical components.
- Co-targeting both Yap1 and Cox2 markedly increased the effectiveness of Gemcitabine treatment in mice, and patient data suggested that combining statins and Cox2 inhibitors with Gemcitabine could enhance survival rates for PDAC patients.